Want to see IN:NECLIFE full AI Analyst Report?
NECLIFE Stock Chart & Stats
₹10.30
-₹0.06(-0.58%)
At close: 4:00 PM EDT
₹10.30
-₹0.06(-0.58%)
Day’s Range― - ―
52-Week Range₹9.20 - ₹22.49
Previous CloseN/A
Volume4.76K
Average Volume (3M)22.67K
Market Cap
₹2.01B
Enterprise Value₹619.87M
Total Cash (Recent Filing)₹1.25B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield20.72%
Share Statistics
EPS (TTM)-11.38
Shares Outstanding194,260,970
10 Day Avg. Volume28,213
30 Day Avg. Volume22,670
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)97.56
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical OfferingsNectar’s presence across APIs, finished dosages, intermediates, and contract services gives it several routes to generate pharmaceutical revenue. This breadth can support customer diversification and provide a platform for recovery if one product category or business line remains weak.
Historically Moderate LeverageHistorically moderate leverage and positive equity provide a stronger capital foundation than a highly indebted balance sheet would. This can preserve some flexibility to stabilize operations or fund recovery, although the company’s recent deterioration limits the practical strength of this benefit.
Prior Positive Cash GenerationPositive operating and free cash flow across FY2022–FY2025 shows that the business has previously converted operations into cash rather than relying continuously on external funding. That history provides evidence of potential cash-generation capability if operating conditions recover.
Bears Say
Revenue CollapseA reported collapse of annual revenue to zero represents a severe disruption to the company’s operating base, not merely slower growth. Sustained weakness at this level would impair customer relationships, fixed-cost absorption, and the ability to rebuild profitable scale over the next several quarters.
Severe Cash BurnVery large negative operating and free cash flow can rapidly consume available liquidity and force dependence on borrowing, asset sales, or new capital. If the cash burn persists, the company may have less capacity to maintain operations, invest in products, or withstand further business disruption.
Unstable ProfitabilityThe swing from near break-even results in FY2024 to meaningful losses in FY2025 and very large losses in FY2026 demonstrates weak earnings consistency. Unstable profitability reduces confidence in sustainable margins and makes internal funding of growth or recovery substantially more difficult.
Nectar Lifesciences Ltd. News
NECLIFE FAQ
What was Nectar Lifesciences Ltd.’s price range in the past 12 months?
Nectar Lifesciences Ltd. lowest stock price was ₹9.20 and its highest was ₹22.49 in the past 12 months.
What is Nectar Lifesciences Ltd.’s market cap?
Nectar Lifesciences Ltd.’s market cap is ₹2.01B.
When is Nectar Lifesciences Ltd.’s upcoming earnings report date?
Nectar Lifesciences Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 18 days.
How were Nectar Lifesciences Ltd.’s earnings last quarter?
Nectar Lifesciences Ltd. released its earnings results on Aug 14, 2026. The company reported -₹0.793 earnings per share for the quarter.
Is Nectar Lifesciences Ltd. overvalued?
According to Wall Street analysts Nectar Lifesciences Ltd.’s price is currently Overvalued.
Does Nectar Lifesciences Ltd. pay dividends?
Nectar Lifesciences Ltd. pays a Annually dividend of ₹4.319 which represents an annual dividend yield of 20.72%. See more information on Nectar Lifesciences Ltd. dividends here
What is Nectar Lifesciences Ltd.’s EPS estimate?
Nectar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nectar Lifesciences Ltd. have?
Nectar Lifesciences Ltd. has 194,260,970 shares outstanding.
What happened to Nectar Lifesciences Ltd.’s price movement after its last earnings report?
Nectar Lifesciences Ltd. reported an EPS of -₹0.793 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nectar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in IN:NECLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nectar Lifesciences Ltd.
Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing services (CRAMS), encompassing process innovation, optimization, and validation, along with production scale-up. This includes the preparation and global submission of drug master files (DMFs) and certificates of suitability, multi-kilo pilot plant manufacturing, large-scale bulk production, and chiral resolution. The company also offers specialized services in chemical and analytical development, as well as providing analytical, manufacturing, and engineering consulting. NLL's product range features a variety of active pharmaceutical ingredients (APIs) and intermediates, prominently including numerous cephalosporin compounds like cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. Additionally, Nectar Lifesciences engages in contract manufacturing for finished dosage forms, producing items such as tablets, capsules, dry powder oral suspensions, granules, and injectables, particularly for cephalosporin medications. Beyond its core pharmaceutical offerings, the company also supplies diagnostic tools, empty hard gelatin capsules, and menthol products.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―